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Abstract
BACKGROUND—Although the mechanisms underlying the causes of heavy menstrual blood
loss (MBL) remain to be elucidated, prostaglandins have been previously implicated. This study
was initiated to elucidate a pattern of expression of the various components of the cyclooxygenase
(COX)–prostaglandin signalling pathways present in the endometrium of women with normal and
heavy MBLs.
METHODS—Endometrial biopsies were collected at different stages of the menstrual cycle from
women who underwent measurement of MBL. Tissue was divided for either examination of gene
expression by quantitative RT–PCR analysis or in vitro culture experimentation.
RESULTS—Analysis of gene expression demonstrated a significant elevation in expression of
COX-1 and COX-2 mRNA in endometrium obtained from women with heavy MBL when
compared with endometrium obtained from women with normal MBL. Tissue culture with PGE2
stimulation caused a significantly elevated production of cyclic AMP (cAMP) by endometrium of
women with heavy MBL when compared with normal MBL. Expression of phosphodiesterase 4B,
an enzyme involved in cAMP breakdown, was reduced in these same endometrial samples
obtained from women with heavy MBL.
CONCLUSIONS—These data identify the E series prostaglandin receptors and their signalling
pathways as potential therapeutic targets in the treatment of heavy menstruation.
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Introduction
Initial studies of menstrual fluid identified vasoactive substances with the capabilities of
inducing contractions in strips of ileal muscle (Pickles, 1957). These were subsequently
identified as prostaglandins F2α (PGF2α) and E2 (PGE2), the two most abundant
prostaglandins found in the endometrium and menstrual fluid (Lumsden et al., 1983).
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Evidence has since continued to mount, supporting a role for prostaglandins in menstruation
(Baird et al., 1996).
In the prostaglandin synthesis pathway, the cyclooxygenase (COX) enzymes generate PGH2
from arachidonic acid. There are two main isoforms of the COX enzyme: COX-1 and
COX-2. COX-1 is constitutively expressed in many tissues and generates prostaglandins for
normal physiological function, whereas COX-2 is rapidly induced in cells in response to
varied stimuli (Vane et al., 1998). Once synthesized, PGH2 acts as an intermediary for a
specific terminal prostaglandin synthase enzyme. Synthesized prostaglandins mediate their
actions via seven-transmembrane G-protein coupled receptors (GPCRs). PGE2 can couple to
four subtypes of GPCRs, which have been pharmacologically classified as EP1, EP2, EP3
and EP4 (Coleman et al., 1994). These receptors are often co-expressed together in the same
cell and, utilize alternate and, in some cases, opposing intracellular signalling pathways
(Ashby, 1998). EP2 and EP4 receptors, previously demonstrated in human endometrium
(Milne et al., 2001), are coupled to G proteins (Gαs) and adenylyl cyclase, resulting in the
increased formation of cyclic AMP (cAMP). PDE4 is a member of the phosphodiesterase
family of enzymes, which has been previously demonstrated in human endometrium
(Bartsch et al., 2004), and is specific for the hydrolysis of cAMP (Sanz et al., 2005). The
level of accumulation of the second messenger, cAMP, in response to prostaglandin
signalling may therefore be dependent on the level of PDE4 activity. The PGE2 pathway has
previously been implicated in the problem of heavy menstrual blood loss (MBL) (Willman
et al., 1976; Smith et al., 1981; Adelantado et al., 1988), although specific signalling
mechanisms have yet to be elucidated. Additional prostaglandins include prostacyclin and
thromboxane, which act upon their respective receptors (IP and TBXR). Prostacyclin and
thromboxane are best known for their effects on the vascular endothelium, where their
synthesis is well noted (Ullrich et al., 2001). Menstruation is an active process whereby the
upper two-thirds of the endometrium, the functional layer, are shed and regenerated on a
cyclical basis. Menstrual problems account for much of the morbidity that occurs in women
of reproductive age. Thirty percentage of women consider their menstruation to be
excessive, rising to 50% in perimenopausal women (Prentice, 1999, 2000). Management
typically involves invasive surgery. In 2002–3, over 13 000 surgical procedures
(hysterectomy and endometrial ablation) were performed in UK for complaints of heavy
bleeding (Reid and Mukri, 2005). An estimated 3.5 million workdays are lost annually
(Weeks et al., 2000).
The objective definition of heavy MBL is often based on the measurement of menstrual
haemoglobin content. This method of measurement was first described in Scandinavian
studies, which demonstrated the mean MBL to be 40 ml. Regular MBL in excess of 63 ml
was associated with iron deficiency anaemia (Hallberg, 1964; Hallberg et al., 1966). The
90th centile for measured blood loss was 80 ml and this has traditionally been accepted as
the upper limit of normal in clinical evaluation of MBL.
Previous investigations into the aetiology of heavy MBL have not been able to discover any
differences in circulating steroid hormone levels (Eldred and Thomas, 1994) or any specific
histological differences within the endometrium (Rees et al., 1984) of women with heavy
MBL when compared with women with normal MBL. Additionally, there is no difference in
endometrial expression of estrogen and progesterone receptors (Critchley et al., 1994).
However, evidence does exist implicating local mediators, in particular, prostaglandins
(Sales and Jabbour, 2003). Increased levels of total prostaglandins have been found in
endometrium taken from women with heavy MBL (Smith et al., 1981). Furthermore,
treatment using inhibitors of COX enzymes has repeatedly been shown to reduce MBL
(Cameron et al., 1990; Coulter et al., 1995; Bonnar and Sheppard, 1996), implicating
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disturbances of prostaglandin pathways in the aetiology of excessive menstrual bleeding,
although the mechanisms underlying the cause of heavy blood loss remain to be elucidated.
This study was initiated to determine a pattern of expression of the various components of
the COX–prostaglandin signalling pathways present in the endometrium of women with
normal and heavy MBLs (>80 ml). This is based on the hypothesis that disturbances of local
mediator signalling, including prostaglandin signalling, are implicated in the aetiology of
heavy MBL.
Materials and methods
Tissue collection and measurement of MBL
Patients complaining of heavy menstruation were recruited from the gynaecological
outpatient setting. Ethical approval was obtained from the Lothian Research Ethics
Committee and written informed consent was obtained from all subjects before tissue
collection. All subjects were aged 18–50 (range 22–49; mean 40 years of age). All subjects
reported regular menstrual cycles (cycle length 21–35 days), with no unscheduled, non-
menstrual bleeding. No woman had received hormonal preparation in the 3 months
preceding biopsy collection. Patients were clinically examined and clinical pelvic
abnormalities, such as an enlarged uterus, were further investigated by pelvic ultrasound
imaging. Patients with known uterine pathology such as fibroid disease and endometriosis
were excluded from the study.
Endometrial biopsies (n = 26) were collected for research purposes at different stages of the
menstrual cycle with an endometrial suction curette (Pipelle, Laboratoire CCD, Paris,
France). No biopsies were taken during the menstrual phase of the cycle because of
technical difficulties in obtaining sufficient quantities of endometrium suitable for RNA
analysis. Biopsies were dated according to stated last menstrual period (LMP) and dating
was confirmed by histological assessment according to criteria of Noyes et al. (1950).
Furthermore, circulating estradiol and progesterone serum levels were measured at the time
of biopsy collection and were consistent for both LMP and histological assessment of the
menstrual cycle stage. This is a robust method for characterizing endometrial samples.
Detailed gene microarray studies support this method for characterizing endometrial
samples with consistency across these three parameters (Critchley et al., 2006; Talbi et al.,
2006).
Inconsistencies between measured circulating hormone levels, stated day of LMP and/or
histological assessment, led to exclusion of three tissue biopsies from the study. Table I
provides a summary of the biopsies (n = 23) used within this work.
Immediately after collection, tissue was divided, transferred into RNA Later (Ambion Inc.,
Huntingdon, UK) and stored at -70°C (for RNA extraction), fixed in neutral-buffered
formalin for wax embedding (for histological dating) and placed in Rosewell Park Memorial
Institute (RPMI) 1640 medium (containing 2 mM L-glutamine, 100 U penicillin and 100 μg
ml-1 streptomycin) and transported to the laboratory for in vitro culture.
In addition to consenting to provide an endometrial biopsy, patients agreed to undergo
measurement of MBL over one menstruation. Measurement was based on a modified
alkaline–haematin method as previously described (Hallberg, 1964). Briefly, used sanitary
products were added to a measured volume of 5% sodium hydroxide (between 2 and 4 l).
The contents were then left for 48 h to allow conversion of haemoglobin to haematin.
During this same time period, a 1 in 200 dilution of the patient’s venous blood in 5% sodium
hydroxide was made and additionally stored. After 48 h, an aliquot of sodium hydroxide was
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removed from the volume soaking the sanitary products and filtered through hardened filter
paper (Whartman No. 54, Maidstone, UK). The optical density (OD) of MBL solution and
venous blood sample were then measured using spectrophotometry at 546 nm (A546).
MBL was then calculated as a quantity of patient’s own venous blood using the following
equation (van Eijkeren et al., 1986):
Validation work for this method of measuring MBL has previously been carried out (data
not shown).
The range of measured MBL was between 10 and 567 ml with a median MBL of 42 ml for
the normal group (MBL >80 ml) and a median MBL of 183 ml for the heavy group (MBL
>80 ml). All patients provided informed consent for collection of an endometrial biopsy
during the month proceeding or immediately following collection of their menstrual loss.
Whole tissue cAMP assay
Endometrial biopsies from proliferative and secretory phases of the menstrual cycle were
minced finely with scissors and incubated overnight in RPMI medium containing 3 μg ml-1
indomethacin (an inhibitor of COX-1 and COX-2 enzymes). Following overnight treatment,
approximately one-third of the tissue was removed and stored at -20°C. The remaining
tissue was incubated in the same medium containing 1 mM 1-methyl-3-isobutylxanthine
(IBMX, Sigma, Poole, UK) for 30 min. (IBMX inhibits the action of phosphodiesterases and
prevents the rapid degradation of cAMP.) It was then divided into two portions and treated
with control medium or 100 nM PGE2 for 10 min. Tissue was then lysed in 0.1 M HCl and
frozen until assayed. Cyclic AMP concentration was measured by enzyme-linked
immunosorbent assay (Biomol, Affiniti, Exeter, UK) in accordance with the manufacturer’s
instructions and normalized to protein concentration determined by protein assay according
to the manufacturer’s instructions (Bio-Rad, Hemel Hempstead, UK).
Taqman quantitative reverse transcriptase–polymerase chain reaction
The expression of COX enzymes across the menstrual cycle and the expression of
prostanoid receptors in endometrium characterized by MBL were investigated by
quantitative RT–PCR. Total RNA was extracted from endometrial biopsies using the
commercially available product RNeasy Midi Kit (Qiagen Ltd, Sussex, UK), according to
the manufacturer’s instructions. Each tissue sample was able to provide sufficient quantities
of RNA for the complete analysis of our target genes. Samples were treated for DNA
contamination by DNA digestion during RNA purification. Following extraction, total RNA
was eluted in 150 μl of nuclease-free water and stored at -80°C. Quality of RNA was
assessed using the Agilent 2100 Bioanalyser system in combination with RNA6000nano
chips (Agilent Technologies, Cheshire, UK). Only RNA that displayed intact 18S and 28S
peaks was reverse transcribed to cDNA for real-time PCR analysis.
Once extracted and quantified, RNA samples were reverse transcribed as previously
described (Milne et al., 2001; Sales et al., 2004). Thereafter, cDNA samples were stored at
-20°C. A tube with no reverse transcriptase was included to control for any DNA
contamination.
Real-time quantitative PCR was performed using an ABI 7700 Sequence Detection System
(Applied Biosystems, Warrington, UK) as previously described (Milne et al., 2001; Sales et
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al., 2004) using duplicate samples. A no-template control (containing water) was included.
The inclusion of ribosomal 18S primers and probes was used to act as a housekeeping gene
for each reaction mix. All primers and probes were designed using the PRIMER express
programme (Applied Biosystems) and their sequences can be found in Table II.
Data were analysed and processed using Sequence Detector version 1.6.3 (Applied
Biosystems) according to manufacturer’s instructions. Expression of target genes was
normalized to RNA loading for each sample using 18S ribosomal RNA as an internal
standard. All results were expressed relative to a control standard (cDNA obtained from a
single sample of endometrial tissue and included in all experiments).
Statistical analysis
The quantitative RT–PCR data did not consistently fulfil the assumptions necessary for
using analysis of variance (ANOVA) and t-test; therefore, the non-parametric Mann–
Whitney test was used (Graphpad InStat3) and statistical significance accepted when P <
0.05. Cyclic AMP assay data were subjected to statistical analysis with ANOVA and Fishers
PLSD tests (Statview 4.0; Abacus Concepts Inc., Piscataway, NJ, USA) and statistical
significance accepted when P < 0.05.
Results
Quantitative RT–PCR analysis of genes involved with prostaglandin signalling
Analysis of mRNA expression for a variety of genes associated with prostanoid signalling
within the endometrium by quantitative RT–PCR was performed. Analysis of COX-1 and
COX-2 mRNA expressions demonstrated a significant increase in secretory endometrium of
women with MBL in excess of 80 ml when compared with endometrium of women with
MBL <80 ml (Figure 1).
No significant differences in endometrial expression were detected for prostacyclin or
thromboxane receptors. Regarding the receptors for PGE2, no significant differences in
expression were detected between the two groups of endometrial samples for EP2, EP3 and
EP4. The mRNA expression of EP1 was significantly increased in secretory endometrium of
women with heavy MBL when compared with normal MBL. Finally, mRNA expression of
the receptor for PGF2α (FP) was significantly reduced in proliferative endometrium of
women with heavy MBL when compared with normal MBL (Figure 2).
Functional PGE2 receptor signalling in endometrium of women with measured MBL
The PGE2 receptors, EP2 and EP4, are known to activate the cAMP/protein kinase A
pathway within the human endometrium (Milne et al., 2001; Regan, 2003). To investigate
the potential differences in PGE2 receptor function between endometrial samples of women
with measured MBL, we therefore looked at cAMP production as an end-point for receptor
function.
Cyclic AMP production in response to treatment with 100 nM PGE2 was higher in
endometrial tissue explants collected from women with heavy MBL when compared with
endometrium of women with normal MBL (Figure 3A).
As described earlier, the analysis of prostanoid receptor mRNA expression did not detect
any significant differences for EP2 or EP4 in endometrium of women with measured MBL.
Therefore, in order to investigate whether effects at the post-receptor level could explain this
enhanced functionality of the EP receptor, we investigated the expression of
phosphodiesterase isotype 4B (PDE4B) in the same endometrial samples. Quantitative RT–
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PCR analysis demonstrated a significant reduction in the expression of PDE4B in secretory
endometrium of women with heavy MBL, compared with normal MBL (Figure 3B).
Discussion
This study demonstrates significantly elevated levels in mRNA expression of both COX-1
and COX-2 enzymes in endometrium obtained from women with measured heavy MBL.
These data suggest that it is important to use a general inhibitor of both COX-1 and COX-2
enzyme action in treating the complaint of heavy menstruation. Mefenamic acid, a COX
inhibitor and a member of the Fenamate family of drugs, is routinely used as a first-line
treatment for menorrhagia. As well as inhibiting prostaglandin synthesis, it has been shown
to inhibit binding of PGE2 to its receptors (Rees et al., 1988). In keeping with this dual mode
of action, the PGE2 pathway has previously been implicated in the problem of heavy MBL.
Elevated levels of PGE2 have been found in the endometrium of women complaining of
heavy periods (Willman et al., 1976) and further experiments confirmed an apparent shift in
synthesis in favour of PGE2 over PGF2α in the endometrium of women with heavy MBL
(Smith et al., 1981).
Additionally, our data demonstrate an enhanced PGE2–EP-induced cAMP production in the
endometrium obtained from women with heavy MBL; however, the expression of EP2 and
EP4 receptors, which are known to couple to cAMP production, does not display any
significant correlation with measured MBL in our studies. Previous data have demonstrated
an increase in PGE2 binding sites in uterine tissue associated with the complaint of heavy
MBL (Adelantado et al., 1988), although specific receptor subtypes were not identified.
Indeed, it is plausible that EP2 and EP4 receptor numbers could be regulated at the post-
transcriptional level, resulting in increased PGE2 receptor binding sites. PGF2α and PGE2
are two prominent prostaglandins found in human endometrium (Lumsden et al., 1986). In
the endometrium, PGF2α receptor (FP) and PGE2 receptors, EP2 and EP4, are responsible
for their respective ligand action. Although there was a reduction in the expression of FP in
the endometrium taken from women with heavy MBL, no changes in the expression of EP2
and EP4 were found. Therefore, a shift of endometrial prostaglandin signalling in favour of
the PGE2 pathway over the PGF2α pathway may exist in the endometrium of women with
heavy MBL. Previous work has shown a decrease in the PGF2α/PGE2 ratio in the
endometrium of women with measured heavy MBL when compared with women with
normal MBL (Smith et al., 1981).
The COX-2–PGE2–EP pathway has previously been shown to influence angiogenic factors
such as vascular endothelial growth factor through a mechanism mediated by cAMP
(Sonoshita et al., 2001). Therefore, the enhanced ability for cAMP production by
endometrium taken from women with heavy MBL may have important effects on the
expression of angiogenic factors. Altered endothelial function as a result of disturbances to
angiogenic factors has previously been implicated in excessive MBL (Kooy et al., 1996).
Thromboxane and prostacyclin are implicated in platelet function and vascular haemostasis
(Grosser et al., 2006) and there is a strong expression of their respective receptors in the
endometrial vascular compartment (Milling Smith et al., 2006; Battersby, unpublished data).
However, no differences in the expression of the genes involved in their signalling pathways
downstream of COX enzymes were detected between the two groups of the endometrium of
women with heavy and normal MBLs.
PDEs are a large family of enzymes that are responsible for the hydrolysis of cyclic
nucleotides (Sanz et al., 2005). PDE4B is an isoenzyme that is found in the human
endometrium (Bartsch et al. 2001, 2004) and shows specificity for hydrolysis of cAMP. We
Smith et al. Page 6
Hum Reprod. Author manuscript; available in PMC 2009 June 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
have shown that in addition to an enhanced ability to produce cAMP in response to PGE2,
endometrium taken from women with heavy MBL expresses a significantly reduced level of
PDE4B isoform mRNA.
In summary, increased expression of the rate-limiting COX enzymes in the endometrium of
women with heavy MBL will lead to an increase in prostaglandin production and signalling.
In addition, enhanced functionality of the EP receptors coupled to cAMP production could
in part be explained by a reduction in PDE4B expression within endometrium of women
with heavy MBL.
Our data, therefore, present a novel mechanism of endometrial prostaglandin signalling that
may lead to the complaint of heavy menstruation. Enhanced COX–PGE2 signalling and
reduced PDE4B expression in the endometrium of women with heavy MBL present us with
new therapeutic opportunities in the treatment of heavy menstrual bleeding.
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Figure 1.
Box plot demonstrating relative cyclooxygenase-1 (COX-1) and COX-2 mRNA expression
in proliferative and secretory endometrium of women with normal and heavy measured
menstrual blood losses (MBLs) (normal MBL ≤80 ml and heavy MBL >80 ml). The data are
presented as box-and-whisker plots: box represents the 25th and 75th percentiles and the
heavy bar represents the median. The whiskers are the 10th and 90th percentiles. NP, normal
proliferative (n = 7); HP, heavy proliferative (n = 5); NS, normal secretory (n = 6); HS,
heavy secretory (n = 5) Asterisk indicates significant difference (P < 0.05).
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Figure 2.
Composite figure of box plot graphs demonstrating relative mRNA expression for
prostanoid receptors in proliferative and secretory endometrium of women with normal and
heavy measured menstrual blood losses (MBLs) (normal MBL ≤80 ml and heavy MBL >80
ml). The data are presented as box-and-whisker plots: box represents the 25th and 75th
percentiles and the heavy bar represents the median. The whiskers are the 10th and 90th
percentiles. NP, normal proliferative (n = 7); HP, heavy proliferative (n = 5); NS, normal
secretory (n = 6); HS, heavy secretory (n = 5). EP1 to EP4 are the receptors for
prostaglandin E2; FP is the receptor for prostaglandin F2α; TBXR is the receptor for
thromboxane and IP is the receptor for prostacyclin. Asterisk indicates significant difference
(P < 0.05).
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Figure 3.
(A) Cyclic AMP (cAMP) production by endometrial tissue explants in response to a 10 min
stimulation with 100 nM PGE2 or vehicle. Graph shows average fold increase in cAMP
production by endometrium of women with normal and heavy menstrual blood losses
(MBLs) (normal MBL ≤80 ml and heavy MBL >80 ml). Asterisk indicates significant
elevated cAMP production (P < 0.05). (B) Phosphodiesterase 4B (PDE4B) mRNA
expression in endometrium of women with normal and heavy MBLs (normal MBL ≤80 ml
and heavy MBL >80 ml) as determined by real-time quantitative RT–PCR. The data are
presented as box-and-whisker plots: box represents the 25th and 75th percentiles and the
heavy bar represents the median. The whiskers are the 10th and 90th percentiles. NP, normal
proliferative (n = 7); HP, heavy proliferative (n = 5); NS, normal secretory (n = 6); HS,
heavy secretory (n = 5). Asterisk indicates significant difference (P < 0.05).
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Table I
Summary of collected endometrial biopsies
Stage of menstrual cycle Number of biopsies
Menstrual blood
loss (MBL) ≤80 ml MBL >80 ml
Proliferative 7 5
Secretory 6 5
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